|
Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
Gene Therapy
|
NCI
|
1R43CA114924-01A2
|
|
Nanoparticles for the Treatment of Lung Cancer
|
CHADA, SUNIL
|
INTROGEN RESEARCH INSTITUTE, INC.
|
TX
|
$234,382
|
Gene Therapy
|
NHLBI
|
7K08HL071613-03
|
|
Novel Strategies for Aerosolized AAV Gene Therapy
|
FISCHER, ANNE
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$128,250
|
Gene Therapy
|
NIAID
|
5R01AI063142-04
|
|
Ad5 Fiber and Penton mts: Influence on immune activation
|
FALCK-PEDERSEN, ERIK
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$390,669
|
Gene Therapy
|
NHLBI
|
1R01HL087285-01A1
|
|
Genetic Modification of Human Hematopoietic Stem Cells with Pseudotyped rAAV
|
CHATTERJEE, SASWATI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$416,042
|
Gene Therapy
|
NIGMS
|
5R01GM042539-17
|
|
Regulation of Tissue Specific Gene Expression
|
GEYER, PAMELA
|
UNIVERSITY OF IOWA
|
IA
|
$329,979
|
Gene Therapy
|
NCI
|
5R01CA115965-02
|
|
FHIT Gene Therapy in Cancer Prevention and Treatment
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
OH
|
$228,000
|
Gene Therapy
|
NHLBI
|
5K99HL088692-02
|
|
HDAd-mediated gene therapy for hemophilia B
|
BRUNETTI-PIERRI, NICOLA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$90,000
|
Gene Therapy
|
NIDDK
|
5R01DK065739-05
|
|
FUNCTIONAL BIOMATERIALS FOR ANTISENSE DELIVERY TO ISLET
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
UT
|
$293,812
|
Gene Therapy
|
NIAID
|
5R01AI039416-12
|
|
Gene Transfer System for AIDS Therapy
|
GARCIA-MARTINEZ, J. VICTOR
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$326,489
|
Gene Therapy
|
NIAID
|
5R01AI067952-03
|
|
AAV and the DNA Damage Machinery
|
WEITZMAN, MATTHEW
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$406,787
|
Gene Therapy
|
NIDDK
|
5R01DK048252-15
|
|
Pathophysiology of Distal Tyrosine Pathway Disorders
|
GROMPE, MARKUS
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$308,500
|
Gene Therapy
|
NHLBI
|
5K08HL083095-02
|
|
Role of Calcium-Activated Chloride Channels in Airway Disease Phenotypes
|
PATEL, ANAND
|
WASHINGTON UNIVERSITY
|
MO
|
$119,718
|
Gene Therapy
|
NHLBI
|
5R01HL076488-04
|
|
Pulmonary Transgene Expression Imaging with PET
|
ROGERS, BUCK
|
WASHINGTON UNIVERSITY
|
MO
|
$444,927
|
Gene Therapy
|
NHLBI
|
1F32HL090350-01
|
|
SERCA2a and Cardiac Alternans: Insights from Gene Therapy
|
CUTLER, MICHAEL
|
METROHEALTH MEDICAL CENTER
|
OH
|
$52,898
|
Gene Therapy
|
NCI
|
5R01CA101837-04
|
|
MnSOD-PL Irradiation Protection of the Oral Cavity
|
GREENBERGER, JOEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$230,171
|
Gene Therapy
|
NHLBI
|
5R01HL075713-05
|
|
OVERCOMING POSITION EFFECTS WITH CHROMATIN INSULATORS
|
EMERY, DAVID
|
UNIVERSITY OF WASHINGTON
|
WA
|
$323,425
|
Gene Therapy
|
NHLBI
|
5R01HL079023-04
|
|
Enhancing hepatocyte gene transfer for Hemophilia A
|
MCCRAY, PAUL
|
UNIVERSITY OF IOWA
|
IA
|
$274,118
|
Gene Therapy
|
NHLBI
|
5R01HL079370-04
|
|
Gene Delivery into Human Hematopoietic Cells
|
BANK, ARTHUR
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$343,479
|
Gene Therapy
|
NIDCD
|
5R01DC006501-05
|
|
Genetic approach for transneuronal NA circuitry mapping
|
KIM, KWANG-SOO
|
MC LEAN HOSPITAL (BELMONT, MA)
|
MA
|
$237,311
|
Gene Therapy
|
NIDDK
|
5R01DK074026-03
|
|
Antioxidant Gene Therapy to Treat Diabetic Neuropathy
|
GOSS, JAMES
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$315,499
|
Gene Therapy
|
NIAID
|
5R01AI041636-11
|
|
Adenovirus as a Vector for Gene Therapy
|
HEARING, PATRICK
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$376,408
|
Gene Therapy
|
NIAID
|
5R01AI063340-04
|
|
Gene Therapy for Athabascan SCID
|
MCIVOR, R
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$306,264
|
Gene Therapy
|
NINDS
|
5R21NS055212-02
|
|
Targeting Gene Delivery to the CNS Blood-Brain Barrier
|
CHEN, IRVIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$202,781
|
Gene Therapy
|
NIDDK
|
5K01DK073367-03
|
|
Targeted Integration of a Lentiviral Vector
|
SINN, PATRICK
|
UNIVERSITY OF IOWA
|
IA
|
$119,670
|
Gene Therapy
|
NHLBI
|
5R01HL080789-03
|
|
Molecular Biology of Recombinant AAV Genomes
|
XIAO, WEIDONG
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$359,939
|
Gene Therapy
|
NCI
|
5R21CA116525-02
|
|
Design of targeted native tropism-ablated adenovirus
|
DMITRIEV, IGOR
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$145,500
|
Gene Therapy
|
NCI
|
5R01CA042992-22
|
|
Liposome and Polycationic Gene Therapy for Osteosarcoma
|
KLEINERMAN, EUGENIE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$263,918
|
Gene Therapy
|
NINDS
|
5R01NS034568-13
|
|
STRATEGIES TO ENHANCE GENE TRANSFER TO THE CNS
|
DAVIDSON, BEVERLY
|
UNIVERSITY OF IOWA
|
IA
|
$323,419
|
Gene Therapy
|
NIAID
|
7R01AI072773-02
|
|
Transduction of Schistosoma mansoni by pseudotyped retrovirus
|
BRINDLEY, PAUL
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$448,408
|
Gene Therapy
|
NINDS
|
5R01NS048441-04
|
|
Development of therapies to retard Parkinson's disease
|
YAGI, TAKAO
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$290,858
|
Gene Therapy
|
NINDS
|
5R01NS054120-03
|
|
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
|
GINNS, EDWARD
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$319,521
|
Gene Therapy
|
NHLBI
|
5R01HL056205-12
|
|
Gene Transfer and Myocardial Function
|
KOCH, WALTER
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$295,832
|
Gene Therapy
|
NHLBI
|
5R01HL086741-02
|
|
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular Surgery
|
LOGERFO, FRANK
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$509,665
|
Gene Therapy
|
NCI
|
5R21CA115568-02
|
|
Design of targeted cell vehicles to ovarian carcinoma
|
PEREBOEVA, LARISA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$174,600
|
Gene Therapy
|
NIGMS
|
5R01GM070837-04
|
|
Integration of Murine Retroviral Vectors
|
ROTH, MONICA
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$208,999
|
Gene Therapy
|
NIAID
|
5R01AI056310-05
|
|
Adeno-associated Virus RNA Splicing and Polyadenylation
|
PINTEL, DAVID
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$272,302
|
Gene Therapy
|
NHLBI
|
5K08HL072865-06
|
|
Gene Therapy for the Wiskott Aldrich Syndrome
|
STROM, TED
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$108,000
|
Gene Therapy
|
NIDDK
|
5R01DK069705-04
|
|
E coli-based vectors for BAC delivery to mammalian cells
|
WARBURTON, PETER
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$274,363
|
Gene Therapy
|
NINDS
|
5R21NS054143-02
|
|
Targeted Toxin for Brain Cancer Gene Therapy
|
CASTRO, MARIA
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$208,688
|
Gene Therapy
|
NEI
|
5R01EY010804-13
|
|
SETTING THE STAGE FOR REPLACEMENT OF MITOCHONDRIAL GENES
|
MORAES, CARLOS
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$419,045
|
Gene Therapy
|
NCI
|
5R01CA076183-06
|
|
Targeting diffuse liver metastases with Herpes virus
|
TANABE, KENNETH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$375,113
|
Gene Therapy
|
NIAID
|
5R01AI051388-05
|
|
AAV Vector Targeting Strategies for Gene Therapy
|
BARTLETT, JEFFREY
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$283,700
|
Gene Therapy
|
NIAID
|
5R21AI069018-02
|
|
Induction of Immunological Tolerance for Gene Therapy
|
ZIMRING, JAMES
|
EMORY UNIVERSITY
|
GA
|
$225,140
|
Gene Therapy
|
NINDS
|
5R21NS058541-02
|
|
Global, Cell Type Specific Modulation of Selected Glutamate Transporters
|
POULSEN, DAVID
|
UNIVERSITY OF MONTANA
|
MT
|
$154,766
|
Gene Therapy
|
NCI
|
5R01CA105171-05
|
|
Combining Virotherapy and Immunotherapy for Cancer
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$300,313
|
Gene Therapy
|
NINDS
|
5R01NS053912-03
|
|
Intrabodies as novel neurological therapeutics
|
MESSER, ANNE
|
WADSWORTH CENTER
|
NY
|
$317,687
|
Gene Therapy
|
NIAID
|
5R01AI068978-03
|
|
Targeting lentiviruses to infect chosen cells
|
WANG, PIN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$574,827
|
Gene Therapy
|
NIBIB
|
5R01EB004657-04
|
|
Design of Gene Delivery System to Target Hepatocytes
|
DAVIS, MARK
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
CA
|
$378,593
|
Gene Therapy
|
NHLBI
|
1R01HL087836-01A1
|
|
In vivo function and tolerance to Factor VIII variants
|
LEE, BRENDAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$383,750
|
Gene Therapy
|
NIBIB
|
5R21EB005331-02
|
|
Human Copper Transporter 1 as Reporter Gene for Imaging
|
PENG, FANGYU
|
WAYNE STATE UNIVERSITY
|
MI
|
$184,363
|
Gene Therapy
|
NINDS
|
5R01NS054193-02
|
|
Gene Therapy and the Brain: Neuroimmune Interactions
|
LOWENSTEIN, PEDRO
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$313,031
|
Gene Therapy
|
NIGMS
|
5R01GM073901-03
|
|
Mechanisms of the AAV2 Rep motor protein
|
LINDEN, R
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$317,236
|
Gene Therapy
|
NCI
|
5R01CA108585-03
|
|
Armed Replicating Ad for Breast Cancer Bone Metastasis
|
DOUGLAS, JOANNE
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$225,695
|
Gene Therapy
|
NHLBI
|
1R01HL090765-01
|
|
HSC transduction in situ by cellular delivery of integrating viral vectors
|
KURRE, PETER
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$380,680
|
Gene Therapy
|
NHLBI
|
1R01HL090921-01
|
|
Cell selection strategies for the gene therapy of the beta-hemoglobinopathies
|
LEBOULCH, PHILIPPE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$424,226
|
Gene Therapy
|
NEI
|
1R01EY018656-01
|
|
Compacted DNA Nanoparticles for Ocular Therapy
|
NAASH, MUNA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$366,250
|
Gene Therapy
|
NIAID
|
1R01AI076652-01
|
|
Cloning major genes for lethal GVHD in mice
|
CAO, THAI
|
UNIVERSITY OF UTAH
|
UT
|
$299,833
|
Gene Therapy
|
NCI
|
5R01CA107070-05
|
|
RGD-Polymer Targeting Plasmid to Angiogenic Endothelium
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
UT
|
$261,534
|
Gene Therapy
|
NEI
|
1R24EY018600-01
|
|
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
|
GUY, JOHN
|
UNIVERSITY OF FLORIDA
|
FL
|
$871,453
|
Gene Therapy
|
NICHD
|
5R01HD052682-02
|
|
Control of Breathing & Glycogen Storage Disease
|
FULLER, DAVID
|
UNIVERSITY OF FLORIDA
|
FL
|
$305,086
|
Gene Therapy
|
NCI
|
5R01CA110176-04
|
|
Nonhuman adenoviral vectors for gene therapy
|
MITTAL, SURESH
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$223,763
|
Gene Therapy
|
NIBIB
|
1R21EB007208-01A2
|
|
Novel gene delivery and expression system
|
LI, SHULIN
|
LOUISIANA STATE UNIV A&M COL BATON ROUGE
|
LA
|
$183,750
|
Gene Therapy
|
NCI
|
5R21CA122693-02
|
|
PET-guided Intervention in Lymphatic Metastasis of Prostate Cancer
|
WU, LILY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$185,400
|
Gene Therapy
|
NINDS
|
5R01NS053540-03
|
|
Non-Viral Gene Targeting to the Brain
|
PARDRIDGE, WILLIAM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$303,790
|
Gene Therapy
|
NINDS
|
5R01NS032677-16
|
|
Genetically Engineered Viruses for Brain Tumor Therapy
|
MARTUZA, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$376,250
|
Gene Therapy
|
NCI
|
1R21CA131774-01
|
|
Small RNA targeted gene activation for the treatment of prostate cancer
|
LI, LONG-CHENG
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$208,238
|
Gene Therapy
|
NIAID
|
2R01AI051390-07A1
|
|
Immunology of Factor IX Gene Transfer to Liver
|
HERZOG, ROLAND
|
UNIVERSITY OF FLORIDA
|
FL
|
$325,028
|
Gene Therapy
|
NIDDK
|
1R01DK080477-01
|
|
ORAL GENE THERAPY WITH NiMOS FOR INFLAMMATORY BOWEL DISEASE
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
MA
|
$333,625
|
Gene Therapy
|
NCI
|
1R21CA132033-01
|
|
Targeted polymeric nanocarriers for combination therapy of prostate cancer
|
FORREST, MARCUS
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$164,470
|
Gene Therapy
|
NCI
|
5R01CA114340-02
|
|
Antiangiogenic Gene Therapy of Ovarian and Breast Cancers
|
RAMAKRISHNAN, SUNDARAM
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$253,417
|
Gene Therapy
|
NCI
|
1R01CA132091-01
|
|
Targeted Nanoparticle DNA Therapy for Ovarian Cancer
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$304,559
|
Gene Therapy
|
NINDS
|
5R21NS052432-02
|
|
Viral vector-based RNAi therapy for Alexander Disease
|
BONTHIUS, DANIEL
|
UNIVERSITY OF IOWA
|
IA
|
$193,594
|
Gene Therapy
|
NCI
|
5R01CA107268-05
|
|
Pharmacology of Targeted Therapy to Brain Tumors
|
SZOKA, FRANCIS
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$364,513
|
Gene Therapy
|
NINDS
|
5K08NS046012-05
|
|
Intrathecal Gene Transfer for Chronic Cancer Pain
|
BEUTLER, ANDREAS
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$168,291
|
Gene Therapy
|
NCI
|
5R01CA102218-05
|
|
TRAIL-induced apoptosis in prostate cancer
|
VOELKEL-JOHNSON, CHRISTINA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$249,182
|
Gene Therapy
|
NIDDK
|
1R01DK077703-01A1
|
|
REDUCIBLE POLYAMIDO ETHYLENIMINE FOR GLP-1 PLASMID DELIVERY
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
UT
|
$262,501
|
Gene Therapy
|
NIDCR
|
5R01DE013397-08
|
|
Gene Therapy for Reconstructing Periodontal Tissues
|
GIANNOBILE, WILLIAM
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$403,105
|
Gene Therapy
|
NCI
|
5R01CA081140-11
|
|
Model for Gene Therapy in X-linked Agammaglobulinemia
|
RAWLINGS, DAVID
|
CHILDREN'S HOSPITAL AND REG MEDICAL CTR
|
WA
|
$297,611
|
Gene Therapy
|
NIGMS
|
5R01GM051449-12
|
|
Cutaneous Wound Repair with Transgenic Skin Cells in Pig
|
ERIKSSON, ELOF
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$372,207
|
Gene Therapy
|
NINDS
|
5R21NS054989-02
|
|
RNAi Gene Silencing of alpha-Synuclein for Parkinson's Disease
|
BOHN, MARTHA
|
CHILDREN'S MEMORIAL HOSPITAL (CHICAGO)
|
IL
|
$160,781
|
Gene Therapy
|
NIDDK
|
5R44DK064469-03
|
|
A new hepatocyte-specific ligand for gene delivery
|
WONG, SO
|
MIRUS BIO CORPORATION
|
WI
|
$617,364
|
Gene Therapy
|
NHLBI
|
5R01HL078836-04
|
|
Evaluation of vectors based on group B adenoviruses
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
WA
|
$283,183
|
Gene Therapy
|
NIDDK
|
5R01DK068343-03
|
|
Mechanism of B-cell Delivered Tolerance in Diabetes
|
SCOTT, DAVID
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$311,976
|
Gene Therapy
|
NIMH
|
1R21MH082421-01
|
|
HSV amplicon vectors for neuroscience research
|
CHIOCCA, E. ANTONIO
|
OHIO STATE UNIVERSITY
|
OH
|
$202,500
|
Gene Therapy
|
NCI
|
1R01CA122930-01A2
|
|
Conditionally Replicative Adenoviral Vectors for Malignant Glioma
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
IL
|
$323,817
|
Gene Therapy
|
NIAID
|
5R01AI033657-14
|
|
Baculovirus envelope proteins and insect cells
|
BLISSARD, GARY
|
BOYCE THOMPSON INST FOR PLANT RESEARCH
|
NY
|
$204,939
|
Gene Therapy
|
NHLBI
|
1R01HL084381-01A2
|
|
Molecular engineering of factor VIII gene for rAAV delivery
|
XIAO, WEIDONG
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$364,302
|
Gene Therapy
|
NIAID
|
5R01AI058697-04
|
|
Overcoming HIV-1 resistance to RNA Interference
|
RAMRATNAM, BHARAT
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$347,418
|
Gene Therapy
|
NIDDK
|
2R01DK038795-20A2
|
|
Krabbe disease: Combined therapies for the central and peripheral nervous systems
|
WENGER, DAVID
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$309,333
|
Gene Therapy
|
NINDS
|
2R01NS035633-10A2
|
|
Gene Therapy and Seizures
|
MCCOWN, THOMAS
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$316,867
|
Gene Therapy
|
NIAID
|
1R01AI072176-01A1
|
|
Rational and combinatorial engineering of AAV vectors
|
SAMULSKI, RICHARD
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$373,669
|
Gene Therapy
|
NIAID
|
5R01AI042552-11
|
|
Combinatorial Use of Anti-HIV RNA-based Therapeutics
|
ROSSI, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$377,840
|
Gene Therapy
|
NIAID
|
5K25AI058672-05
|
|
Multiscale studies of HIV infection and treatment
|
CHOU, TOM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$126,886
|
Gene Therapy
|
NHLBI
|
1R01HL088426-01A1
|
|
Translational Studies of AAV Gene Transfer for CHF
|
HAMMOND, H KIRK
|
VETERANS MEDICAL RESEARCH FDN/SAN DIEGO
|
CA
|
$346,250
|
Gene Therapy
|
NEI
|
2R01EY012155-11
|
|
Deactivation of Visual Pigments in vivo
|
CHEN, JEANNIE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$649,278
|
Gene Therapy
|
NIA
|
1R01AG030048-01A1
|
|
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
|
AISEN, PAUL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$2,095,517
|
Gene Therapy
|
NHLBI
|
5R01HL053670-14
|
|
Lentiviral Vectors for Gene Transfer
|
VERMA, INDER
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$635,999
|
Gene Therapy
|
NHLBI
|
5R01HL064274-08
|
|
Hepatic Gene Transfer for Treatment of Hemophilias A&B
|
KAY, MARK
|
STANFORD UNIVERSITY
|
CA
|
$513,056
|
Gene Therapy
|
NCI
|
5R01CA121258-02
|
|
Cellular Transduction with Replication-Competent Retrovirus Vectors
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$467,899
|
Gene Therapy
|
NINDS
|
5F32NS054453-02
|
|
Targeting Therapeutic Gene Vectors to Reactive Glia
|
XU, JIANFENG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$58,036
|
Gene Therapy
|
NINDS
|
5R01NS053559-03
|
|
Pathogenesis and possible therapies modelled in ovine Batten disease
|
PALMER, DAVID
|
LINCOLN UNIVERSITY
|
NEW ZE
|
$268,384
|
Gene Therapy
|
NINDS
|
2R01NS045855-05A1
|
|
Promoters for Long-term Expression from HSV-1 Vectors
|
GELLER, ALFRED
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$253,378
|
Gene Therapy
|
NEI
|
5R01EY005951-22
|
|
Oxidative damage and cone cell death in RP
|
CAMPOCHIARO, PETER
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$508,409
|
Gene Therapy
|
NEI
|
5R01EY016861-02
|
|
Exploring plasticity of the adult visual system using viral gene delivery
|
NEITZ, MAUREEN
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$371,175
|
Gene Therapy
|
NIDDK
|
5R01DK042716-16
|
|
Protection from GVHD with Gene-Modified Donor T Cells
|
NASH, RICHARD
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$377,773
|
Gene Therapy
|
NINDS
|
5R21NS053770-02
|
|
Silencing mutant SOD1 in vivo for treatment of ALS
|
XU, ZUOSHANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$178,403
|
Gene Therapy
|
NIDDK
|
5R01DK056845-09
|
|
Establishment and maintenance of repressed chromatin
|
BOUHASSIRA, ERIC
|
YESHIVA UNIVERSITY
|
NY
|
$363,163
|
Gene Therapy
|
NIAID
|
5R01AI057066-05
|
|
SiRNA Gene Therapy for HIV/AIDS
|
AKKINA, RAMESH
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
CO
|
$303,468
|
Gene Therapy
|
NHLBI
|
5R01HL077421-04
|
|
Stem Cell Therapy for Pulmonary Hypertension
|
KADOWITZ, PHILIP
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$413,096
|
Gene Therapy
|
NCI
|
5R01CA080192-09
|
|
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
WA
|
$226,398
|
Gene Therapy
|
NEI
|
5R01EY001919-32
|
|
Cellular Mechanisms of Inherited Retinal Degeneration
|
LAVAIL, MATTHEW
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$634,272
|
Gene Therapy
|
NEI
|
5R01EY011731-11
|
|
Rhodopsin Gene Correction and Gene Knockout in Rod Cells
|
WILSON, JOHN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$402,085
|
Gene Therapy
|
NEI
|
5K08EY017024-03
|
|
non-viral medicated gene targeting to the retina
|
CHUNG, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$145,025
|
Gene Therapy
|
NCI
|
5R01CA119298-03
|
|
Glioma Therapy Using Targeted Oncolytic HSV Vectors
|
GLORIOSO, JOSEPH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$349,393
|
Gene Therapy
|
NINDS
|
1R21NS054768-01A2
|
|
Gene therapy for Ataxia Telangiectasia
|
CORTES, MARIA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$210,300
|
Gene Therapy
|
NCI
|
5R01CA120327-02
|
|
Molecular Imaging of Cancer In vivo via Targeted Transduction
|
CHEN, IRVIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$234,840
|
Gene Therapy
|
NEI
|
5R01EY017294-02
|
|
Gene therapy in the cornea
|
MOHAN, RAJIV
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$329,082
|
Gene Therapy
|
NIAMS
|
5R01AR049537-06
|
|
Altered Matrix-Cells and Intermolecular Interactions
|
FERTALA, ANDRZEJ
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$338,358
|
Gene Therapy
|
NIAID
|
5R01AI064344-04
|
|
MODULATION OF REGULATORY TOLERANCE TO TRANSPLANTS
|
LEGUERN, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$515,180
|
Gene Therapy
|
NHLBI
|
4R37HL033610-23
|
|
Brain Angiotensin In Hypertensive Neurons in Culture
|
RAIZADA, MOHAN
|
UNIVERSITY OF FLORIDA
|
FL
|
$686,851
|
Gene Therapy
|
NIMH
|
5R01MH070287-05
|
|
Targeting HIV infection of the cns using gene delivery
|
STRAYER, DAVID
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$372,161
|
Gene Therapy
|
NIAID
|
5R01AI069350-03
|
|
Retargeting of Retroviral Vectors
|
CHEN, IRVIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$341,020
|
Gene Therapy
|
NCI
|
5R01CA109446-05
|
|
Recombinant Immunotherapy for Renal Cell Carcinoma
|
GRIFFITH, THOMAS
|
UNIVERSITY OF IOWA
|
IA
|
$258,035
|
Gene Therapy
|
NIDDK
|
5K01DK063992-05
|
|
Gene therapy for Cooley's anemia in a new mouse model
|
RIVELLA, STEFANO
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$129,133
|
Gene Therapy
|
NIDDK
|
5R01DK072537-03
|
|
Tolerance Induction by Neonatal Gene Delivery
|
GAENSLER, KARIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$301,145
|
Gene Therapy
|
NCI
|
5R21CA125327-02
|
|
Nanoscale Functional Dendrimer-DNA Assemblies
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY
|
MA
|
$162,500
|
Gene Therapy
|
NIDDK
|
5R01DK059371-05
|
|
AAV2/8 vector-mediated liver gene therapy for phenylketonuria (PKU)
|
HARDING, CARY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$279,677
|
Gene Therapy
|
NIAID
|
5R01AI074043-02
|
|
In Vivo ADA Gene Delivery for the Treatment of SCID
|
KOHN, DONALD
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$483,204
|
Gene Therapy
|
NIDDK
|
5R01DK055759-10
|
|
Gene Targeting by Adeno-Associated Virus Vectors
|
RUSSELL, DAVID
|
UNIVERSITY OF WASHINGTON
|
WA
|
$309,913
|
Gene Therapy
|
NIDDK
|
5R01DK066212-04
|
|
Proteosome Inhibitor Enhanced Non-Viral Gene Delivery
|
RICE, KEVIN
|
UNIVERSITY OF IOWA
|
IA
|
$250,387
|
Gene Therapy
|
NCI
|
5R01CA104873-05
|
|
HPV helper functions for AAV Replication
|
HERMONAT, PAUL
|
UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
|
AR
|
$227,407
|
Gene Therapy
|
NHLBI
|
5R01HL076901-06
|
|
Human Parvovirus B19 Vectors: Mechanism of Transduction
|
SRIVASTAVA, ARUN
|
UNIVERSITY OF FLORIDA
|
FL
|
$344,900
|
Gene Therapy
|
NIDDK
|
5R01DK058702-07
|
|
Episomal lenti vector for a humanized hemophilia mouse
|
KAFRI, TAL
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$262,949
|
Gene Therapy
|
NHLBI
|
5R01HL081148-04
|
|
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids
|
DEAN, DAVID
|
UNIVERSITY OF ROCHESTER
|
NY
|
$373,835
|
Gene Therapy
|
NHLBI
|
5R01HL083047-02
|
|
Aerosol delivery of HDAd into Primate Lungs: Preclinical CF Gene Therapy Studies
|
NG, PHILIP
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$704,125
|
Gene Therapy
|
NCI
|
5R21CA122213-02
|
|
Novel oncolytic adenovirus for pancreatic therapy
|
KIM, BAEK
|
UNIVERSITY OF ROCHESTER
|
NY
|
$215,600
|
Gene Therapy
|
NIAMS
|
5R37AR040864-19
|
|
Dystrophin Replacement in mdx mice
|
CHAMBERLAIN, JEFFREY
|
UNIVERSITY OF WASHINGTON
|
WA
|
$504,779
|
Gene Therapy
|
NINDS
|
5R01NS038690-07
|
|
AAV Gene Therapy for the CNS in MPS VII
|
WOLFE, JOHN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$446,473
|
Gene Therapy
|
NCI
|
5R01CA125272-02
|
|
Cellular co-factors in stable retroviral transduction
|
DANIEL, RENE
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$235,600
|
Gene Therapy
|
NIAID
|
5R01AI065429-04
|
|
Innate immunity to adenovirus vectors
|
SHAYAKHMETOV, DMITRY
|
UNIVERSITY OF WASHINGTON
|
WA
|
$282,026
|
Gene Therapy
|
NIDDK
|
1R41DK076516-01A2
|
|
A novel approach for gene therapy
|
MAAS, STEFAN
|
ATIGEN
|
PA
|
$139,916
|
Gene Therapy
|
NCI
|
1R43CA128278-01A1
|
|
Functional Vectors for Treatment of Mesothelioma
|
BALABAI, NATALIA
|
FIFTH BASE, LLC
|
FL
|
$165,920
|
Gene Therapy
|
NHLBI
|
1R13HL091555-01
|
|
2008 Viral Vectors for Gene Therapy, The Science of Gordon Research Conference
|
ROBBINS, PAUL
|
GORDON RESEARCH CONFERENCES
|
RI
|
$15,000
|
Gene Therapy
|
NIDDK
|
5R01DK065656-05
|
|
CARP: Angiogenic Gene Therapy in Diabetic Wounds
|
DAVIDSON, JEFFREY
|
VANDERBILT UNIVERSITY
|
TN
|
$283,068
|
Gene Therapy
|
NCI
|
5R01CA049248-19
|
|
Hepatic Metabolism of Anti-cancer Drugs
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
MA
|
$275,637
|
Gene Therapy
|
NIDDK
|
5R01DK061408-07
|
|
HGF Gene Therapy for Chronic Renal Fibrosis
|
LIU, YOUHUA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$258,446
|
Gene Therapy
|
NHLBI
|
5R01HL083017-02
|
|
Preclinical gene correction of hemophilia A
|
KAZAZIAN, HAIG
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$395,386
|
Gene Therapy
|
NCI
|
5R01CA109711-04
|
|
Gene Delivery Modulated by Redox Potential Gradients
|
OUPICKY, DAVID
|
WAYNE STATE UNIVERSITY
|
MI
|
$249,211
|
Gene Therapy
|
NCI
|
5R21CA116014-02
|
|
A NOVEL TARGETED THERAPEUTIC USING VIRAL CAPSID PROTEIN
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$190,800
|
Gene Therapy
|
NIDDK
|
5R01DK068399-03
|
|
Non-viral Liver-targeted Gene Delivery
|
MAO, HAI-QUAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$283,668
|
Gene Therapy
|
NIA
|
2R42AG026174-02A2
|
|
Cell-Based, Chronic Wound Gene Therapy for Older Adults
|
ALLEN-HOFFMANN, LYNN
|
STRATATECH CORPORATION
|
WI
|
$401,433
|
Gene Therapy
|
NINDS
|
5R01NS055143-02
|
|
TH and GTPCHI gene therapy for Parkinson's disease
|
KORDOWER, JEFFREY
|
RUSH UNIVERSITY MEDICAL CENTER
|
IL
|
$465,614
|
Gene Therapy
|
NEI
|
5R01EY010581-12
|
|
Therapies for Photoreceptor Degeneration
|
LI, TIANSEN
|
MASSACHUSETTS EYE AND EAR INFIRMARY
|
MA
|
$179,611
|
Gene Therapy
|
NHLBI
|
1R43HL086213-01A1
|
|
Facilitation of Autologous Hematopoietic Stem Cell Engraftment for Gene Therapy
|
DOWN, JULIAN
|
GENETIX PHARMACEUTICALS, INC.
|
MA
|
$249,705
|
Gene Therapy
|
NCI
|
5R01CA070337-12
|
|
Combination gene therapy for metastatic colon cancer
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$287,106
|
Gene Therapy
|
NHLBI
|
7R01HL081499-03
|
|
Novel Molecular and Cellular Therapies in Fanconi Anemia
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$325,790
|
Gene Therapy
|
NCI
|
5R01CA060999-13
|
|
pRb2/p130: from the mechanisms to gene therapy
|
GIORDANO, ANTONIO
|
TEMPLE UNIVERSITY
|
PA
|
$321,078
|
Gene Therapy
|
NINDS
|
5K08NS046430-04
|
|
Targeted Adenoviral Gene Therapy for Malignant Glioma
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
IL
|
$165,078
|
Gene Therapy
|
NIDA
|
1R43DA023374-01A1
|
|
Chronic pain therapy through upregulation of opioid receptors
|
WANG, CONGYING
|
MAJESTECK BIOSCIENCE
|
TX
|
$219,917
|
Gene Therapy
|
NCI
|
2P01CA094237-06
|
9002
|
VECTOR PRODUCTION
|
GEE, ADRIAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$294,859
|
Gene Therapy
|
NHLBI
|
5R13HL072168-07
|
|
Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
|
TARANTAL, ALICE
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$10,000
|
Gene Therapy
|
NIAID
|
5R13HL072168-07
|
|
Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
|
TARANTAL, ALICE
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$5,000
|
Gene Therapy
|
NIBIB
|
5R13HL072168-07
|
|
Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
|
TARANTAL, ALICE
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$3,000
|
Gene Therapy
|
NCI
|
5R01CA092487-05
|
|
Oncolytic adenovector-mediated TRAIL gene therapy for cancers
|
FANG, BINGLIANG
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$314,553
|
Gene Therapy
|
NIAMS
|
5R21AR055712-02
|
|
Muscle-specific AAV Vectors for DMD Gene Therapy
|
SAMULSKI, RICHARD
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$153,811
|
Gene Therapy
|
NINDS
|
1F31NS059283-01A1
|
|
Targeting Amyloid Beta Oligomers in the 3xTg-AD Mouse Model with scFv Antibodies
|
RYAN, DEBORAH
|
UNIVERSITY OF ROCHESTER
|
NY
|
$40,972
|
Gene Therapy
|
NCI
|
7R01CA107621-04
|
|
Engineering Polymers For Gene Therapy of Head Cancer
|
SWAAN, PETER
|
UNIVERSITY OF UTAH
|
UT
|
$281,835
|
Gene Therapy
|
NEI
|
5R01EY016470-03
|
|
Gene Delivery in Retinal Diseases
|
NICKERSON, JOHN
|
EMORY UNIVERSITY
|
GA
|
$327,582
|
Gene Therapy
|
NIAID
|
5R01AI043619-11
|
|
Tolerance to allografts through gene therapy
|
IACOMINI, JOHN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$300,442
|
Gene Therapy
|
NINDS
|
1F31NS056780-01A2
|
|
Inducing Tolerance to Gene Transfer in Dystrophic Mice
|
EGHTESAD, SAMAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$40,972
|
Gene Therapy
|
NINDS
|
2P01NS040923-06A1
|
0006
|
Vector delivery to modify the brain tumor and its microenvironment
|
GLORIOSO, JOSEPH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$273,580
|
Gene Therapy
|
NIGMS
|
1F32GM083594-01
|
|
Gene correction in hematopoitic stem cells using a retargetable meganuclease
|
VOLLES, MICHAEL
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$52,898
|
Gene Therapy
|
NCI
|
5R01CA100893-05
|
|
Use of Adjuvants to Improve Skin Genetic Immunizations
|
LARREGINA, ADRIANA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$256,287
|
Gene Therapy
|
NCI
|
5R01CA107082-04
|
|
T Cell Based Carriers for In Vivo Gene Therapy of Cancer
|
VILE, RICHARD
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$279,026
|
Gene Therapy
|
NEI
|
1F31EY018082-01A2
|
|
Signal transduction pathways involved in adult cortical plasticity
|
PENA, JOHN
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$49,681
|
Gene Therapy
|
NIDCR
|
5R01DE013386-07
|
|
COMBINATORIAL GENE THERAPY FOR BONE REGENERATION
|
FRANCESCHI, RENNY
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$325,604
|
Gene Therapy
|
NHLBI
|
5R44HL076908-03
|
|
Transposon-Mediated Gene Therapy for Fanconi Anemia
|
MCIVOR, R
|
DISCOVERY GENOMICS, INC.
|
MN
|
$566,484
|
Gene Therapy
|
NHLBI
|
5R01HL073838-04
|
|
rAAV-Mediated Gene Therapy for Hemophillia B
|
DAVIDOFF, ANDREW
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$355,568
|
Gene Therapy
|
NCI
|
5R01CA116621-04
|
|
Her2-targeted vectors for gene therapy of cancer
|
KRASNYKH, VICTOR
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$322,144
|
Gene Therapy
|
NCI
|
5R01CA106298-05
|
|
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$285,864
|
Gene Therapy
|
NCI
|
5R01CA111569-04
|
|
Capsid-labeled adenovirus for virotherapy monitoring
|
CURIEL, DAVID
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$262,662
|
Gene Therapy
|
NCI
|
5R01CA085939-09
|
|
Improving Suicide Genes for Cancer Gene Therapy
|
BLACK, MARGARET
|
WASHINGTON STATE UNIVERSITY
|
WA
|
$263,260
|
Gene Therapy
|
NIAMS
|
5R01AR050595-06
|
|
Gene Therapy for a severe DMD Animal Model
|
XIAO, XIAO
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$297,689
|
Gene Therapy
|
NCI
|
5R01CA113662-04
|
|
DNA Damage Targeted Gene Therapy in Head & Neck Cancer
|
WEICHSELBAUM, RALPH
|
UNIVERSITY OF CHICAGO
|
IL
|
$263,390
|
Gene Therapy
|
NHLBI
|
5R01HL088467-02
|
|
Safe, Silencing-Resistant, Non-Oncogenic Globin Expression Cassettes
|
BOUHASSIRA, ERIC
|
YESHIVA UNIVERSITY
|
NY
|
$477,970
|
Gene Therapy
|
NCI
|
5R01CA089325-07
|
|
Regulation of Targeted Gene Correction
|
KMIEC, ERIC
|
UNIVERSITY OF DELAWARE
|
DE
|
$210,384
|
Gene Therapy
|
NEI
|
5R01EY014026-05
|
|
Oligonucleotide Repair of a Retinal Degeneration Model
|
BOATRIGHT, JEFFREY
|
EMORY UNIVERSITY
|
GA
|
$363,992
|
Gene Therapy
|
NEI
|
5R01EY009357-14
|
|
Vasculogenesis and hyperoxia in the developing retina.
|
LUTTY, GERARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$312,118
|
Gene Therapy
|
NIBIB
|
5R01EB005658-03
|
|
Reversing Electrostatic Interactions for Improved Gene Delivery
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY
|
MA
|
$336,476
|
Gene Therapy
|
NIBIB
|
5R21EB006520-02
|
|
Parallel gene delivery from spinal cord bridges
|
SHEA, LONNIE
|
NORTHWESTERN UNIVERSITY
|
IL
|
$173,588
|
Gene Therapy
|
NCI
|
5R01CA118022-03
|
|
Hamster Model for Oncolytic Adenovirus Vectors
|
WOLD, WILLIAM
|
SAINT LOUIS UNIVERSITY
|
MO
|
$253,359
|
Gene Therapy
|
NCI
|
5R01CA102139-05
|
|
Genetically Engineered Viruses for Prostate Cancer Therapy
|
MARTUZA, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$340,161
|
Gene Therapy
|
NIDDK
|
5R01DK069968-04
|
|
Growth Factor and Antiapoptotic Gene Delivery to Human Islets
|
MAHATO, RAM
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$238,771
|
Gene Therapy
|
FIC
|
1R01AG029798-01A1
|
|
Neuroprotective Gene Therapy in the Brain of Senile Rats
|
GOYA, RODOLFO
|
NATIONAL UNIVERSITY OF LA PLATA
|
ARGENT
|
$25,000
|
Gene Therapy
|
NIA
|
1R01AG029798-01A1
|
|
Neuroprotective Gene Therapy in the Brain of Senile Rats
|
GOYA, RODOLFO
|
NATIONAL UNIVERSITY OF LA PLATA
|
ARGENT
|
$130,975
|
Gene Therapy
|
NIDDK
|
5R01DK053244-12
|
|
Molecular Remedy of Mitochondrial Defects
|
YAGI, TAKAO
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$331,043
|
Gene Therapy
|
NIDDK
|
5R01DK058318-09
|
|
Accessing the Airway for Cystic Fibrosis Gene Therapy
|
DAVIS, PAMELA
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$334,100
|
Gene Therapy
|
NHLBI
|
5R01HL083078-02
|
|
Translational studies in Heart Failure Gene Therapy
|
BRIDGES, CHARLES
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$727,681
|
Gene Therapy
|
NIA
|
5R01AG025509-04
|
|
AAV Gene Therapy for Alzheimer's Disease
|
MORGAN, DAVID
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$408,989
|
Gene Therapy
|
NIAID
|
5R01AI073255-02
|
|
Humanized Rag2-/-gammac-/-mice for HIV infection and gene therapy
|
AKKINA, RAMESH
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
CO
|
$360,518
|
Gene Therapy
|
NCI
|
5R01CA116322-02
|
|
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor
|
JI, LIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$292,600
|
Gene Therapy
|
NINDS
|
5R21NS059518-02
|
|
Directed Evolution of Adeno-Associated Virus Vectors for Seizure Gene Therapy
|
MCCOWN, THOMAS
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$157,404
|
Gene Therapy
|
NHLBI
|
1R21HL091808-01
|
|
Allele-Specific Repair of the CFTR DeltaF508 Mutation using Zinc Finger Nucleases
|
MCCRAY, PAUL
|
UNIVERSITY OF IOWA
|
IA
|
$215,500
|
Gene Therapy
|
NCI
|
5R01CA074042-11
|
|
Tissue Specific Gene Therapy for Human Prostate Cancer
|
KAO, CHINGHAI
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$265,033
|
Gene Therapy
|
NCI
|
5R01CA116591-03
|
|
Polymer Based Gene Delivery
|
KABANOV, ALEXANDER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$260,726
|
Gene Therapy
|
NINDS
|
5R01NS051644-03
|
|
Ischemic Spasticity: Modulation by GAD65 Gene Delivery
|
MARSALA, MARTIN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$337,544
|
Gene Therapy
|
NCI
|
5U01CA084306-10
|
|
Investigation of lung tumor development and treatment
|
JACKS, TYLER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$870,330
|
Gene Therapy
|
NEI
|
5R24EY017540-02
|
|
Adult Stem Cells for Therapy of Visual Disorders
|
FRIEDLANDER, MARTIN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$3,346,543
|
Gene Therapy
|
NCI
|
5R01CA107492-04
|
|
Prevention of insertional mutagenesis in gene therapy
|
BAUM, CHRISTOPHER
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$224,720
|
Gene Therapy
|
NCI
|
5K08CA103859-04
|
|
Image-guided Gene and Virotherapy for Pancreatic Cancer
|
CARLSON, STEPHANIE
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$131,220
|
Gene Therapy
|
NINDS
|
5R01NS057558-02
|
|
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors
|
GELLER, ALFRED
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$253,378
|
Gene Therapy
|
NCI
|
5R01CA122568-02
|
|
Ligand-Directed Tumor Targeting in Preclinical Models
|
PASQUALINI, RENATA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$292,600
|
Gene Therapy
|
NCI
|
5R01CA100830-06
|
|
Oncolytic VSV for Hepatocellular Carcinoma
|
WOO, SAVIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$338,076
|
Gene Therapy
|
NIDDK
|
5R01DK068216-04
|
|
COMPREHENSIVE GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS VII
|
ROY-CHOWDHURY, JAYANTA
|
YESHIVA UNIVERSITY
|
NY
|
$324,718
|
Gene Therapy
|
NIAID
|
5R01AI039126-14
|
|
Foamy Virus Vector for Immunodeficiency Viruses Therapy
|
MERGIA, AYALEW
|
UNIVERSITY OF FLORIDA
|
FL
|
$323,362
|
Gene Therapy
|
NCI
|
5R01CA115527-02
|
|
Targeting Nanoparticle DNA Delivery to Prostate Tumors
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$310,762
|
Gene Therapy
|
NIBIB
|
5R01EB004533-04
|
|
Somatostatin Receptor Based PET Imaging of Gene Transfer
|
ROGERS, BUCK
|
WASHINGTON UNIVERSITY
|
MO
|
$288,754
|
Gene Therapy
|
NHLBI
|
5R01HL057619-11
|
|
Mouse Model of Sickle Cell Disease and Genetic Therapies
|
TOWNES, TIM
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$426,051
|
Gene Therapy
|
NINDS
|
5R01NS044576-06
|
|
Somatic Cell Gene Transfer/Neurological & Clinical Applications
|
DURING, MATTHEW
|
OHIO STATE UNIVERSITY
|
OH
|
$329,559
|
Gene Therapy
|
NIAMS
|
5K08AR049201-05
|
|
Gene Therapy for Cartilage Injury
|
BERTONE, ALICIA
|
OHIO STATE UNIVERSITY
|
OH
|
$124,713
|
Gene Therapy
|
NHLBI
|
5R01HL085693-03
|
|
Gene therapy for Fanconi anemia
|
KIEM, HANS-PETER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$638,503
|
Gene Therapy
|
NIAMS
|
5R03AR054955-02
|
|
Adult muscle stem cells as cell therapy in utrophin-dystrophin deficient mice
|
REYES, MORAYMA
|
UNIVERSITY OF WASHINGTON
|
WA
|
$81,340
|
Gene Therapy
|
NHLBI
|
5R13HL078311-05
|
|
Conference--American Society of Gene Therapy
|
KOHN, DONALD
|
AMERICAN SOCIETY OF GENE THERAPY
|
WI
|
$10,000
|
Gene Therapy
|
NINDS
|
5R01NS041584-07
|
|
Determinants that regulate splicing of SMN
|
LORSON, CHRISTIAN
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$326,620
|
Gene Therapy
|
NCI
|
2P01CA094060-06A1
|
0001
|
Mouse Models for Tumor Progression and Maintenance
|
VARMUS, HAROLD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$407,911
|
Gene Therapy
|
NIDDK
|
5R01DK068134-03
|
|
Oxidative Stress and Vascular HO in Diabetes
|
ABRAHAM, NADER
|
NEW YORK MEDICAL COLLEGE
|
NY
|
$310,166
|
Gene Therapy
|
NCRR
|
5K01RR019979-05
|
|
Neuropathology of a Mouse Model for Phenylketonuria
|
EMBURY, JENNIFER
|
UNIVERSITY OF FLORIDA
|
FL
|
$111,998
|
Gene Therapy
|
NHLBI
|
5R01HL081527-02
|
|
Engineering AAV Vectors to Evade Antibody Neutralization
|
SCHAFFER, DAVID
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$361,214
|
Gene Therapy
|
NINDS
|
5R01NS055165-02
|
|
STEM/PROGENITOR CELL PROTECTION FOR PARKINSON'S DISEASE
|
STEINDLER, DENNIS
|
UNIVERSITY OF FLORIDA
|
FL
|
$317,742
|
Gene Therapy
|
NHLBI
|
5R01HL065519-07
|
|
Molecular Chimerism Therapy for Hemophilia A
|
HAWLEY, ROBERT
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$371,408
|
Gene Therapy
|
NHLBI
|
5R01HL066565-08
|
|
Mechanisms of Cardiopulmonary Gene Transfer
|
DIAMOND, SCOTT
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$314,579
|
Gene Therapy
|
NIDCR
|
5K22DE015612-05
|
|
A Novel Herpesviral Vector for Oral Gene Delivery
|
DENG, HONGYU
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$135,000
|
Gene Therapy
|
NHLBI
|
5R01HL081582-04
|
|
Sleeping Beauty Gene Therapy from Liver to BOECs
|
STEER, CLIFFORD
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$354,382
|
Gene Therapy
|
NCI
|
5R01CA109451-04
|
|
Gene Delivery Vehicles for Cancer Gene Therapy
|
MARINI, FRANK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$183,473
|
Gene Therapy
|
NIAMS
|
5R03AR054929-02
|
|
The study of gene therapy for aseptic loosening using a mouse implant model
|
YANG, SHANG-YOU
|
WAYNE STATE UNIVERSITY
|
MI
|
$73,745
|
Gene Therapy
|
NCI
|
5R01CA081171-08
|
|
Viral Proteins: Gene Delivery to Specific Malignancies
|
ALBRITTON, LORRAINE
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$249,183
|
Gene Therapy
|
NIBIB
|
1R21EB008951-01
|
|
First-Principles, Computer-Aided Nanosystem Design and Analysis
|
ORTOLEVA, PETER
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$269,500
|
Gene Therapy
|
NINDS
|
5R21NS057556-02
|
|
Neurovascular Mechanisns of Brain Function and Disease
|
LIU, PHILIP
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$190,837
|
Gene Therapy
|
NIBIB
|
5R01EB005740-04
|
|
NOVEL MARKERS FOR IMAGING GENE EXPRESSION IN VIVO USING MRI
|
AHRENS, ERIC
|
CARNEGIE-MELLON UNIVERSITY
|
PA
|
$310,120
|
Gene Therapy
|
NICHD
|
1P01HD057247-01
|
0001
|
Immune Barriers to AAV Gene Therapy
|
WILSON, JAMES%
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$122,894
|
Gene Therapy
|
NICHD
|
1P01HD057247-01
|
0002
|
Preclinical Studies of AAV Gene Therapy in MOuse Models of Urea Cycle Disorders
|
WILSON, JAMES%
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$122,883
|
Gene Therapy
|
NICHD
|
1P01HD057247-01
|
0003
|
Molecular Characterization of Liver Gene Transfer and Its Oncogenic Potential
|
GAO, GUANG-PING%
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$122,883
|
Gene Therapy
|
NICHD
|
1P01HD057247-01
|
9001
|
Vector Core
|
JOHNSTON, JULIE%
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$122,883
|
Gene Therapy
|
NICHD
|
1P01HD057247-01
|
9003
|
Animal Models Core
|
HANKENSON, CLAIRE%
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$122,883
|
Gene Therapy
|
NIBIB
|
5R01EB005441-03
|
|
Electroporation System for Cutaneous Gene Transfer
|
HELLER, RICHARD
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$315,300
|
Gene Therapy
|
NIAID
|
5R37AI029329-20
|
|
Enhancing the Intracellular Functioning of anti-HIV RNAs
|
ROSSI, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$645,362
|
Gene Therapy
|
NHLBI
|
5R01HL077844-04
|
|
CFTR Delivery to Ciliated Airway Cells by PIV Vectors
|
PICKLES, RAYMOND
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$344,505
|
Gene Therapy
|
NIAMS
|
5R01AR047981-08
|
|
Strategies Towards Gene Therapy for Dystrophic Epidermolysis Bullosa
|
CHEN, MEI
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$333,218
|
Gene Therapy
|
NCI
|
5R01CA121153-02
|
|
Development of Highly Targeted, Imageable Adenoviral Vectors for Prostate Cancer
|
RODRIGUEZ, RONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$311,600
|
Gene Therapy
|
NINDS
|
5F31NS058224-02
|
|
Delivery of a Myostatin Inhibitor by AAV Gene Therapy for Muscular Dystrophy
|
HAIDET, AMANDA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$31,003
|
|